FDA clears Fresenius plasma collector, making donation quicker and easier

Aurora Xi Plasmapheresis System--Courtesy of Fresenius Kabi

The FDA cleared Fresenius Kabi’s plasma collection system that accelerates the plasma collection process, facilitating plasma donation for donors and center operators alike.

Plasma is used in the treatment of burn victims as well as people with bleeding disorders and human immune deficiencies. In plasma donation, a plasmapheresis system draws whole blood via a needle in a donor’s vein. It then separates the plasma from the red blood cells and other cellular components, which are then returned to the donor’s body.

Fresenius Kabi’s Aurora Xi Plasmapheresis System has a proprietary filtration-separation method that allows it to collect plasma faster, according to a statement.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“Faster collection times mean more throughput for our customers, helping maximize the volumes of plasma they collect while assuring a good experience for plasma donors,” said Dean Gregory, president Fresenius Kabi USA’s medical devices unit, in the statement.

In addition to its plasmapheresis offerings, Fresenius Kabi markets pharmaceuticals and tech for infusion, transfusion and clinical nutrition for the care of critically and chronically ill patients. These include cell separators and intravenous solutions.

Suggested Articles

Philips is cementing its commitment to becoming a healthcare technology provider, with plans to split off or sell its consumer appliances division.

A new digital health startup is exiting stealth mode with its advanced, long-lasting patient monitoring device—and touting a quick FDA clearance.

The FDA granted an expanded indication to GT Medical’s GammaTile cancer therapy, broadening its use to newly diagnosed brain cancer patients.